Vericel (VCEL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

VCEL · Stock Price

USD 35.13-6.60 (-15.82%)

Market Cap: $1.7B

Historical price data

Overview

Vericel is a revenue-generating biopharmaceutical company with a mission to provide life-enhancing cell therapies for serious medical conditions in sports medicine and burn care. The company has achieved significant commercial success with its FDA-approved products MACI (for knee cartilage defects) and Epicel (for severe burns), and has expanded its portfolio through the North American licensing of NexoBrid® for burn eschar removal. Its strategy centers on deepening market penetration for its commercial products, pursuing label expansions, and leveraging its proprietary autologous cell therapy manufacturing platform to address adjacent high-need therapeutic areas.

Sports Medicine / OrthopedicsSevere Burn Care

Technology Platform

Proprietary autologous cell therapy platform for harvesting, expanding, and re-implanting a patient's own cells (chondrocytes, keratinocytes) on specialized scaffolds for tissue repair and regeneration.

Pipeline

15

15 drugs in pipeline5 in Phase 3

Drug	Indication	Stage
Carticel (autologous cultured chondrocyte) implantation	Articular Cartilage	Approved
Ixmyelocel-T	Critical Limb Ischemia	Phase 3
autologous cultured chondrocytes on porcine collagen membran...	Articular Cartilage Defect	Phase 3
Ixmyelocel-T	Osteonecrosis	Phase 3
autologous cultured chondrocytes on porcine collagen membran...	Chondral Defect	Phase 3

Funding History

2

Total raised:$70M

PIPE$40MUndisclosedDec 15, 2014

IPO$30MUndisclosedJun 26, 1997

Opportunities

Near-term growth is driven by the recent FDA approvals for arthroscopic delivery of MACI (expanding patient access) and the pediatric label for NexoBrid (entering a new market segment).

Long-term, the Phase 3 trial for MACI in ankle defects represents a major market expansion opportunity, potentially doubling the addressable patient population for its core platform.

Risk Factors

Key risks include commercial concentration on MACI, making the company vulnerable to reimbursement changes; the complex, high-cost autologous manufacturing process which carries operational and supply chain risks; and the potential for clinical failure in its Phase 3 ankle trial, which is critical for future growth.

Competitive Landscape

Vericel enjoys a strong competitive position with first-mover advantage and regulatory exclusivity. MACI is the only FDA-approved autologous cultured chondrocyte product for knee cartilage repair. In burn care, Epicel has HDE exclusivity for massive burns, and NexoBrid competes with surgical debridement and other enzymatic agents. The primary competition comes from established surgical techniques and emerging tissue engineering technologies.

More companies in Cell & Gene Therapy →More companies in United States →